Armistice Capital’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $87.4M | Sell |
1,071,395
-1,003,054
| -48% | -$72.4M | 1.07% | 12 |
|
|
2026
Q1 | $141M | Sell |
2,074,449
-727,420
| -26% | -$51.5M | 2.51% | 4 |
|
|
2025
Q4 | $213M | Sell |
2,801,869
-475,403
| -15% | -$34.5M | 2.53% | 3 |
|
|
2025
Q3 | $201M | Sell |
3,277,272
-1,458,192
| -31% | -$76M | 2.98% | 3 |
|
|
2025
Q2 | $231M | Sell |
4,735,464
-699,379
| -13% | -$33.2M | 3.99% | 3 |
|
|
2025
Q1 | $277M | Sell |
5,434,843
-943,157
| -15% | -$47.1M | 4.15% | 3 |
|
|
2024
Q4 | $288M | Sell |
6,378,000
-856,898
| -12% | -$36.7M | 3.93% | 3 |
|
|
2024
Q3 | $268M | Buy |
7,234,898
+272,671
| +4% | +$9.13M | 4.29% | 3 |
|
|
2024
Q2 | $213M | Buy |
6,962,227
+198,227
| +3% | +$6.42M | 2.68% | 3 |
|
|
2024
Q1 | $197M | Sell |
6,764,000
-100,000
| -1% | -$2.8M | 2.61% | 3 |
|
|
2023
Q4 | $189M | Buy |
6,864,000
+714,000
| +12% | +$16.3M | 2.58% | 3 |
|
|
2023
Q3 | $138M | Buy |
6,150,000
+2,914,000
| +90% | +$108M | 2.11% | 4 |
|
|
2023
Q2 | $132M | Buy |
3,236,000
+312,000
| +11% | +$15.3M | 1.9% | 6 |
|
|
2023
Q1 | $142M | Sell |
2,924,000
-472,000
| -14% | -$21.6M | 2.04% | 6 |
|
|
2022
Q4 | $130M | Buy |
3,396,000
+496,000
| +17% | +$20.6M | 2.26% | 6 |
|
|
2022
Q3 | $146M | Sell |
2,900,000
-396,000
| -12% | -$19.4M | 2.53% | 5 |
|
|
2022
Q2 | $132M | Buy |
3,296,000
+260,000
| +9% | +$9.12M | 2.3% | 6 |
|
|
2022
Q1 | $113M | Buy |
3,036,000
+2,118,893
| +231% | +$81.6M | 2.19% | 6 |
|
|
2021
Q4 | $36.5M | Sell |
917,107
-1,678,893
| -65% | -$64.3M | 0.6% | 41 |
|
|
2021
Q3 | $96.6M | Buy |
2,596,000
+504,000
| +24% | +$20.7M | 1.64% | 12 |
|
|
2021
Q2 | $88.4M | Buy |
2,092,000
+696,000
| +50% | +$29.8M | 1.58% | 10 |
|
|
2021
Q1 | $66.1M | Buy |
1,396,000
+680,000
| +95% | +$40.4M | 1.52% | 15 |
|
|
2020
Q4 | $43.7M | Sell |
716,000
-8,000
| -1% | -$472K | 1.49% | 17 |
|
|
2020
Q3 | $33.8M | Buy |
724,000
+224,000
| +45% | +$11M | 1.23% | 26 |
|
|
2020
Q2 | $25.4M | Sell |
500,000
-100,000
| -17% | -$4.91M | 1.11% | 38 |
|
|
2020
Q1 | $26.8M | Sell |
600,000
-158,000
| -21% | -$7.96M | 1.66% | 20 |
|
|
2019
Q4 | $36.4M | Buy |
758,000
+622,000
| +457% | +$26.4M | 2.1% | 10 |
|
|
2019
Q3 | $4.6M | Buy |
+136,000
| New | +$5.92M | 0.3% | 55 |
|
|
2019
Q2 | – | Sell |
-400,000
| Closed | -$15.1M | – | 80 |
|
|
2019
Q1 | $15.1M | Buy |
400,000
+100,000
| +33% | +$3.36M | 0.82% | 31 |
|
|
2018
Q4 | $10.3M | Buy |
+300,000
| New | +$10.8M | 0.78% | 30 |
|
Other funds holding PTCT
RI
JT
Armistice Capital's PTCT Position: Q2 2026 in Review
Armistice Capital reduced its PTC Therapeutics (PTCT) stake by 48% in Q2 2026, selling an estimated $72.4M and leaving 1,071,395 shares worth $87.4M. The position accounts for 1.07% of the portfolio, ranked #12.
Armistice Capital first reported a position in PTCT in Q4 2018 and has held it in 30 quarters since. The position peaked at $288M in Q4 2024. 383 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Armistice Capital held 1,071,395 shares of PTC Therapeutics worth $87.4M as of Q2 2026.
- Armistice Capital sold 1,003,054 PTC Therapeutics shares in Q2 2026, an estimated $72.4M.
- PTC Therapeutics made up 1.07% of Armistice Capital's portfolio in Q2 2026, its #12 holding.
- Armistice Capital first reported a position in PTC Therapeutics in Q4 2018 and has held it in 30 quarters since.
- Armistice Capital's PTC Therapeutics position peaked at $288M in Q4 2024.
- 383 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.